• Publications
  • Influence
Landscape of somatic mutations in 560 breast cancer whole genome sequences
We analysed whole genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. 93Expand
  • 1,030
  • 52
  • PDF
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
CONTEXT Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies. OBJECTIVE To develop a predictor of response andExpand
  • 424
  • 45
  • PDF
Bone imaging in metastatic breast cancer.
Bone is the most common site to which breast cancer metastasizes. Imaging-by skeletal scintigraphy, plain radiography, computed tomography, or magnetic resonance imaging-is an essential part, andExpand
  • 474
  • 32
  • PDF
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
BACKGROUND Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed withExpand
  • 347
  • 23
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Purpose: The clinical relevancy of the 7-subtype classification of triple-negative breast cancer (TNBC) reported by Lehmann and colleagues is unknown. We investigated the clinical relevancy of TNBCExpand
  • 412
  • 17
  • PDF
Inflammatory Breast Cancer: The Disease, the Biology, the Treatment
Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. It is characterized by rapid progression, local and distantExpand
  • 260
  • 17
Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
Currently, there is extensive information about circulating tumor cells (CTC) and their prognostic value; however, little is known about other characteristics of these cells. In this prospectiveExpand
  • 161
  • 8
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer
Allogeneic stem cell transplantation is employed in patients with relapsed and refractory Hodgkin's lymphoma. In this setting, transplant-related mortality is particularly high. Fludarabine-melphalanExpand
  • 126
  • 8
  • PDF
Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.
PURPOSE To analyze factors that predict the use of trimodality treatment (chemotherapy, surgery, and radiation therapy [RT]) and evaluate the impact that trimodality treatment use has on survival forExpand
  • 74
  • 8
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody directed against HER-2. The objective response rate to trastuzumab monotherapy is 12–34% for a median duration of 9 months, byExpand
  • 246
  • 7